6. CONCLUSION
A possible strategy of pharmacological research may focus on a targeted
action in the lungs and renouncing specific molecular antiviral actions.
This strategy takes into consideration the great variability that the
virus could develop in the future. In light of the above and in
consideration of the tight deadlines, it’s clear that trials on small
volatile molecules could lead to positive results. These results can be
expected both from a prevention point of view and in slowing down and/or
inhibiting the progression of the disease (against the virus) from the
initial stages to the more severe phases (against the cytokine storm).
This perspective is reinforced by the negligible side effects and,
therefore, the positive risk/benefit ratio. A suggested approach could
be to start with the already characterized volatile compounds from the
points of view of safety and known effectiveness against viruses, for
example, 1,8-cineole. In conclusion, a deeper clinical investigation
could be reasonable.